Milciclib-mediated CDK2 inhibition to boost radiotherapy sensitivity in colorectal cancer
Milciclib exhibits antitumor activity in CRC cells as a monotherapy and enhances the effectiveness of radiotherapy when used in combination. It disrupts the G2/M checkpoint and impairs DNA repair mechanisms. These findings suggest that Milciclib has the potential to be an effective therapeutic agent for CRC.
Authors
- Xinxin Yang (ORCID: https://orcid.org/0000-0002-2024-4307)
- Bo Zhang (ORCID: https://orcid.org/0000-0002-6546-8443)
- Haitao Zhu (ORCID: https://orcid.org/0000-0002-4168-4053)
- Junjie Ma (ORCID: https://orcid.org/0000-0001-8693-3335)
- Nengming Lin (ORCID: https://orcid.org/0000-0001-5202-802X)
- Shuying Shen
- Youyou Yan (ORCID: https://orcid.org/0000-0002-5582-2373)
- Wei Xu (ORCID: https://orcid.org/0000-0002-2228-998X)
- Yue Li (ORCID: https://orcid.org/0000-0003-3747-1482)
- Shanshan Wu (ORCID: https://orcid.org/0009-0007-9695-8051)
- Ruoqi Wang (ORCID: https://orcid.org/0009-0005-6989-1926)
- Yiqian Zhu
Institutions
- Zhejiang Chinese Medical University (CN)
- Westlake University (CN)
- Affiliated Hangzhou First People's Hospital, Westlake University, School of Medicine (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-03-25
- DOI
- https://doi.org/10.3389/fphar.2025.1557925
- Citations
- 1
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 1.52